Form 4: Natera CEO Sells Shares for Tax Obligations

Natera's CEO, Steven Leonard Chapman, sold common stock totaling 5,970 shares to cover tax withholding obligations related to RSU vesting.

Summary

• Steven Leonard Chapman, CEO and President of Natera, Inc. and a Director, sold a total of 5,970 shares of Natera common stock.
• The sales occurred on January 27, 2026, and January 28, 2026.
• On January 27, 2026, 2,322 shares were sold at a price of $240.5313 per share.
• On January 28, 2026, 3,648 shares were sold at a price of $237.6624 per share.
• These transactions were conducted to satisfy tax withholding and remittance obligations associated with the vesting of Restricted Stock Units (RSUs).
• The sales were executed under a Rule 10b5-1(c) plan, indicating pre-planned transactions.
• Following these transactions, Mr. Chapman beneficially owns 213,180 shares of Natera common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sales are routine, pre-planned, and for tax purposes, not signaling a change in insider sentiment or company fundamentals.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating pre-planned transactions and not a discretionary sale based on new information.
• The purpose of the sales was explicitly stated as satisfying tax withholding obligations related to RSU vesting, which is a common and routine event for executives.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes are a common occurrence in the biotechnology and diagnostics industry, particularly for executives whose compensation includes significant equity components like Restricted Stock Units (RSUs). These sales are typically not indicative of a change in management's outlook on the company's prospects but rather a routine financial event.

Comparison to Industry Standards

• This type of transaction, a sale of shares to cover tax obligations upon RSU vesting, is standard practice across all industries, including biotechnology.
• There are no specific comparable companies or projects mentioned in the filing to assess against industry-specific results.
• The volume of shares sold (5,970 shares) is relatively small compared to the total beneficial ownership (213,180 shares), which is consistent with typical tax-related sales rather than a significant divestment.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, pre-planned tax-related sales by an insider, not indicative of a change in company fundamentals or insider confidence. The volume is relatively small compared to total shares outstanding.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this routine insider transaction.

Key Dates

Recommendation

This Form 4 filing details routine, pre-planned sales by Natera's CEO to cover tax obligations associated with RSU vesting. Such transactions are common and generally do not reflect a change in the company's fundamental outlook or the insider's long-term confidence. Therefore, a seasoned investor would likely maintain their current position, as this filing provides no new information to warrant a change in investment strategy.

Keywords

Natera, NTRA, Steven Leonard Chapman, CEO, Director, stock sale, Form 4, insider trading, RSU, restricted stock units, tax withholding, 10b5-1 plan